Search PubMed⌕ Search

Biomedical subjects

Sanjay Gupta

Publications and source records attributed to Sanjay Gupta.

At least 217 records · Page 12Linked to original sources

Real-World Outcomes of Once-Daily Risperidone Dosing.

BACKGROUND: Recent reports have shown that risperidone, which has established antipsychotic efficacy, is effective and safe in a once-daily dosing regimen. METHOD: The efficacy and safety of once-daily risperidone were assessed in a retrospective study of 27 patients with a variety of psychiatric disorders who were attending a community day treatment program. Their DSM-IV diagnoses included schizophrenia, schizoaffective disorder, bipolar disorder, major depression with psychosis, and posttraumatic stress disorder. They had received once-daily risperidone for a mean of more than 18 months. RESULTS: Disorders of most patients were controlled with once-daily dosages of 1 to 6 mg/day of risperidone. The nighttime once-daily risperidone dosage was well tolerated by patients. In addition, there was no increase in antipsychotic-related side effects, and compliance was enhanced. CONCLUSION: Risperidone was well tolerated, and no patient needed antiparkinsonian medications even at high dosages of risperidone once daily.

Journal Article↗

Topiramate in Bipolar and Schizoaffective Disorders: Weight Loss and Efficacy.

BACKGROUND: Although useful in bipolar disorder, mood stabilizers, such as lithium, divalproex sodium, and carbamazepine, can cause significant weight gain. METHOD: We conducted a retrospective chart review of 5 patients with DSM-IV bipolar disorder or schizoaffective disorder who were treated with topiramate as adjunctive therapy or monotherapy. RESULTS: All 5 patients had a good response to treatment at a mean topiramate dose of 195 mg/day (range, 100-375 mg/day). All patients lost a substantial amount of weight on topiramate treatment. The average weight loss was 22 lb (10 kg; range, 8-56 lb [4-25 kg]). None of the patients discontinued topiramate because of side effects. CONCLUSION: Topiramate may represent a valuable alternative to existing mood stabilizers, either as an adjunct or as monotherapy in patients with bipolar disorder or schizoaffective disorder.

Journal Article↗

CT-guided needle biopsy of deep pelvic lesions by extraperitoneal approach through iliopsoas muscle.

We report our experience with computed tomography (CT)-guided coaxial needle biopsy of deep pelvic lesions by an extraperitoneal approach through the iliopsoas muscle, using a curved needle for difficult-to-reach lesions. We reviewed the records of all patients with pelvic masses who underwent CT-guided percutaneous biopsy via iliopsoas muscle between January 1999 and December 2001. Direct anterior or posterior approach to the lesion was obstructed by bowel, bladder, vessels, or bones in all patients. An 18-gauge guide needle was advanced through the iliopsoas muscle and a 22-gauge Chiba needle was used to perform the biopsy. A custom-tailored curved 22-g needle was used in 17 procedures when the location of the iliac vessels and the slope of the iliac wing obstructed a straight path to the lesion. Fifty-three patients underwent 57 CT-guided needle biopsies during the study period. The lesions comprised obturator (n = 25), internal iliac (n = 11), anterior external iliac (n = 4), and common iliac nodes (n = 4); soft tissue masses along pelvic side-wall (n = 6); adnexal lesions (n = 5); a loculated fluid collection, and a perirectal node. All lesions were safely accessed, and major vessels and viscera were avoided in all cases. Of the 57 biopsies, 53 (93%) yielded diagnostic specimens. No major complications were encountered. CT-guided coaxial needle biopsy by an anterolateral approach through the iliopsoas muscle, with the use of a curved needle in selected cases is safe and effective for obtaining samples from deep pelvic lesions.

Adult↗

New techniques in image-guided percutaneous biopsy.

Image-guided percutaneous biopsy is a well-established and safe technique for obtaining tissue specimens from various regions of the body and plays a crucial role in patient management. Improvements in needle designs, development of new biopsy techniques, and continual advances in image-guidance technology have improved the safety and efficacy of the procedure. Lesions previously considered relatively inaccessible can now be safely biopsied. This review looks at the recent technologic developments in image guidance for percutaneous biopsy procedures. Improvements in needle design and other innovations intended to enhance the diagnostic yield of biopsy specimens are briefly discussed. Also described are some new techniques and unconventional approaches that help provide safe access to difficult-to-reach lesions.

Biopsy, Needle↗

Out-of-plane computed-tomography-guided biopsy using a magnetic-field-based navigation system.

The purpose of this article is to report our clinical experience with out-of-plane computed-tomography (CT)-guided biopsies using a magnetic-field-based navigation system. Between February 2002 and March 2003, 20 patients underwent CT-guided biopsy in which an adjunct magnetic-field-based navigation system was used to aid an out-of-plane biopsy approach. Eighteen patients had an underlying primary malignancy. All biopsies involved the use of a coaxial needle system in which an outer 18G guide needle was inserted to the lesion using the navigation system and an inner 22G needle was then used to obtain fine-needle aspirates. Complications and technical success were recorded. Target lesions were located in the adrenal gland (n = 7), liver (n = 6), pancreas (n = 3), lung (n = 2), retroperitoneal lymph node (n = 1), and pelvis (n = 1). The mean lesion size (maximum transverse diameter) was 26.5 mm (range: 8-70 mm) and the mean and median cranial-caudal distance, between the transaxial planes of the final needle tip location and the needle insertion site, was 40 mm (range: 18-90 mm). Needle tip positioning was successfully placed within the lesion in all 20 biopsies. A diagnosis of malignancy was obtained in 14 biopsies. Benign diagnoses were encountered in the remaining six biopsies and included a benign adrenal gland (n = 2), fibroelastic tissue (n = 1), hepocytes with steatosis (n = 2) and reactive hepatocytes (n = 1). No complications were encountered. A magnetic-field-based navigation system is an effective adjunct tool for accurate and safe biopsy of lesions that require an out-of-plane CT approach.

Adult↗

Aripiprazole: review of its pharmacology and therapeutic use in psychiatric disorders.

The discovery of antipsychotic medications has revolutionized the treatment of schizophrenia and other psychotic disorders. However, side effects such as extrapyramidal symptoms (EPS) and tardive dyskinesia (TD), electrocardiogram (ECG) changes, weight gain, and metabolic disturbances indicate the continued need to develop new agents. The introduction of atypical drugs such as clozapine, risperidone, olanzapine, quetiapine, and ziprasidone has widened our choices. This article provides an overview of the pharmacology, efficacy, and techniques for the clinical use of aripiprazole, a novel agent with a unique pharmacological profile.

Antipsychotic Agents↗

A review of antioxidants and Alzheimer's disease.

BACKGROUND: In this article, we review a diverse body of research and draw conclusions about the usefulness, or lack there-of, of specific antioxidants in the prevention of Alzheimer's disease (AD). METHODS: The National Library of Medicine's database was searched for the years 1996-2004 using the search terms "Alzheimer's, anti-oxidants, antioxidants." RESULTS: Over 300 articles were identified and 187 articles were selected for inclusion based on relevance to the topic. Agents that show promise in helping prevent AD include: 1) aged garlic extract, 2) curcumin, 3) melatonin, 4) resveratrol, 5) Ginkgo biloba extract, 6) green tea, 7) vitamin C and 8) vitamin E. CONCLUSIONS: While the clinical value of antioxidants for the prevention of AD is often ambiguous, some can be recommended based upon: 1) epidemiological evidence, 2) known benefits for prevention of other maladies, and 3) benign nature of the substance. Long-term, prospective studies are recommended.

Acetylcarnitine↗

Variable effects of psychosocial factors on the clinical course of schizophrenia.

BACKGROUND: Recent work suggests that psychosocial stress factors play a lesser role (qualitatively) in the progression of schizophrenic illness in male patients. The authors endeavored to determine if hospitalization in schizophrenic patients of both sexes is associated with less quantifiable psychosocial stress over time. METHODS: Male and female, schizophrenic inpatients from 2 urban centers in New York State (n = 31) were enrolled in this retrospective and cross-sectional study. Linear regression analysis was performed with illness duration as the independent variable and ln (1 + Paykel Life Events Schedule) score, associated with current hospitalization, as the dependent variable. RESULTS: Linear regression analysis revealed an inverse relationship (slope = -.086) that was statistically significant (p < .01). This result indicates an annual 92% reduction in the psychosocial stress load associated with hospitalization. The inverse relationship remained intact when males and females were analyzed separately. CONCLUSIONS: The data suggest that, over time, male and female patients with schizophrenia experience hospitalization and, likely, relapse as well in response to less of a total significance load of psychosocial stress.

Adult↗

U.S. national trends in the use of antipsychotics during office visits, 1998-2002.

BACKGROUND: There is a paucity of studies on U.S. national trends in the use of antipsychotic medications in the 21st century. This study examined national trends in the prescribing of antipsychotic drugs in office-based physician practices. METHODS: National probability sample survey data from 1998-2002 National Ambulatory Medical Surveys were used to analyze the prescribing trends. The weighted visit estimates and percentages were compared across the years using z-test. RESULTS: The number of antipsychotic-related visits was found to increase significantly and nearly two-fold, from 4.6 million in 1998 to 8.6 million in 2002. During the same period, the number of visits for second-generation antipsychotic drugs nearly tripled. The proportion of visits for the second-generation agents, as a percentage of visits for all antipsychotic drugs, rose sharply from about 48% in 1998 to 84% in 2002. Correspondingly, the percentage of visits involving first-generation antipsychotic drugs declined. The growth in the number of visits involving antipsychotic drugs over the 5-year period was substantial (120%) in visits with non-psychiatrist physicians, but not in visits involving psychiatrists. CONCLUSIONS: The trend of growth in prescription of antipsychotic drugs in office visits, accounted by increased use of second-generation antipsychotics, has persisted into the 21st century. Increased prescribing of these agents by non-psychiatrists is also apparently fueling this trend. This trend of shift from first-to-second generation antipsychotic agents, though not unambiguously supported by extant safety and efficacy data, is endorsed by guidelines based on expert-consensus and limited data. Given the high-level use of second-generation drugs, more practical studies of these drugs, focusing on effectiveness or long-term outcomes, are needed.

Antipsychotic Agents↗

Prescribing conventional antipsychotics in the era of novel antipsychotics: informed consent issues.

The goal of this study was to ascertain why patients are maintained on conventional antipsychotics and whether the risks/benefits and alternative treatments with novel antipsychotics are discussed with these patients. We reviewed the charts of 117 outpatients maintained on conventional antipsychotics at three New York hospitals: Hutchings Psychiatric Center (HPC), Syracuse Veterans Affairs Medical Center (SVA), and the Continuing Day Treatment Program (CDT). The major reasons for maintaining patients on conventional antipsychotics were good response (50%), patient choice (45%), and physician choice (36%). Despite the high incidence of tardive dyskinesia at all three hospitals (range: 12%-50%), physicians often did not discuss the risks/benefits of continuing conventional antipsychotics with the patients. The treating psychiatrist discussed alternative treatments with 37% of patients at SVA, 58% at HPC, and 68% at CDT (P = 0.066, df = 2, Pearson chi(2) test). For patients who are receiving any antipsychotic therapy, discussions about the risks/benefits of treatments are integral for optimal treatment and medicolegal purposes.

Akathisia, Drug-Induced↗

Comorbidity of irritable bowel syndrome in psychiatric patients: a review.

Irritable bowel syndrome (IBS), a functional gastrointestinal disorder, is present in 10% to 20% of the U.S. adult population. The syndrome is best defined as chronic abdominal discomfort with changes in stool frequency, consistency, and passage, with associated symptoms such as abdominal bloating or presence of mucus in stools. Several studies have shown that up to 70% to 90% of patients with IBS who seek treatment have psychiatric comorbidity, most notably mood and anxiety disorders. Recent studies have shown a high prevalence of IBS in psychiatric patients who seek treatment, with a prevalence of 19% in schizophrenia, 29% in major depression, and 46% in panic disorder among other disorders. Our article reviews the comorbidity of IBS in psychiatric patients and discusses implications for treatment.

Colonic Diseases, Functional↗

Hyperglycemia and hypertriglyceridemia in real world patients on antipsychotic therapy.

There have been recent reports in the psychiatric literature of the possible association of glucose dysregulation and diabetes mellitus with the use of atypical antipsychotics. This article describes a retrospective chart review of patients from various clinical settings, including a continuing day treatment program, two inpatient programs, and a large private practice. Information was obtained with regard to weight, fasting blood glucose, lipid profiles, EKG changes, and medical comorbidities. The patients included those treated with conventional antipsychotic agents, clozapine, risperidone, olanzapine, and quetiapine. No one antipsychotic agent was associated with a statistically significantly higher prevalence of diabetes, lipid abnormalities, or EKG problems. It was noted, however, that there were higher rates of diabetes (17%), lipid abnormalities (43%), and hypertension (30%) across the sample. This finding suggests that the high prevalence of diabetes, lipid abnormalities, and hypertension in a young, chronically psychiatrically ill population makes the case for aggressive screening.

Adult↗

Hepatic artery embolization and chemoembolization for treatment of patients with metastatic carcinoid tumors: the M.D. Anderson experience.

BACKGROUND: Carcinoid tumors have a predilection for metastasizing to the liver. The presence of liver metastases is associated with poor prognosis and also results in significant deterioration of patient's quality of life. Several reports suggest that hepatic artery embolization or chemoembolization can be used for control of liver disease in these patients. We retrospectively reviewed our experience with the use of hepatic arterial embolization or chemoembolization in patients with liver-dominant metastatic carcinoid disease, evaluating the clinical and radiologic response rates, duration of response, and progression-free and overall survival rates of these patients. MATERIALS AND METHODS: The medical records of all patients with carcinoid tumors metastatic to the liver who underwent hepatic artery embolization or chemoembolization between January 1992 and December 2000 were reviewed. For the purposes of this study, we compared the follow-up computed tomography or magnetic resonance imaging with the baseline imaging to determine each patient's objective tumor response. The interval between the dates of response and disease progression was considered the response duration. Progression-free survival duration was calculated from the date of initial treatment to the date disease progression was recorded or the date of death. Survival durations were calculated using the Kaplan-Meier method. RESULTS: Eighty-one patients (48 men and 33 women; age range, 38-79 years) were included in this study. The mean duration of disease from the initial discovery of liver metastases until embolization was 24.5 months. Fifty patients were treated with bland hepatic artery embolization, and 31 underwent chemoembolization. Of the 69 patients in whom radiologic response could be evaluated, partial response was observed in 46 patients (67%), minimal response (MR) in six (8.7%), stable disease in 11 (16%), and progressive disease in six (8.7%). The median duration of response in the 42 patients with partial response was 17 months (range, 4-51 months). Sixty-three percent of patients had a reduction in their tumor-related symptoms. The median progression-free survival duration was 19 months (95% confidence interval, 17-21 months); the probability of progression-free survival was 75%, 35%, and 11% at 1, 2, and 3 years, respectively. The median overall survival time was 31 months (95% confidence interval, 23-38 months); the survival probability was 93% at 1 year, 62% at 2 years, and 24% at 5 years. CONCLUSIONS: Hepatic arterial occlusive therapy using hepatic artery embolization or chemoembolization results in symptomatic and radiologic response in most patients with carcinoid metastases in the liver. The progression-free survival of 19 months achieved with embolization in our study is encouraging, given that most patients had extensive liver involvement and had shown disease progression while receiving systemic treatment.

Adult↗